CNCR

Loncar Cancer Immunotherapy ETF
--

61
*Unless otherwise stated, data provided by FactSet.

CNCR Fund Description

CNCR tracks the Loncar Cancer Immunotherapy Index, an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs.

CNCR Factset Analytics Insight

CNCR takes a novel approach to niche coverage within the health care sector. It provides equal- weighted exposure to about 30 companies of various sizes that have approved immunotherapy cancer drugs on the US or European markets or that are engaged in human clinical trials of such drugs. The fund seeks a holistic exposure to the immunotherapy space, specifically including companies with varying drug mechanisms. Equal-weighting the securities draws attention to smaller companies with room to grow. While it’s still too soon to access performance, this fund provides a unique option for investors placing a highly specialized bet on this space.

CNCR MSCI ESG Analytics Insight

Loncar Cancer Immunotherapy ETF has an MSCI ESG Fund Rating of BB based on a score of 3.31 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Loncar Cancer Immunotherapy ETF ranks in the 11st percentile within its peer group and in the 17th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

CNCR Charts And Performance

Price Chart ($)
Total Return Chart (%)
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
  • 1 Month
  • 3 Months
  • YTD
  • 1 Year
  • 3 Years
  • 5 Years
  • Max
Compare
Reset
Select ETFs to compare their performance:
PERFORMANCE [as of 09/19/19] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
CNCR 0.01% -4.91% 5.65% -18.08% -7.60% -- --
CNCR (NAV) -0.35% -4.14% 6.34% -18.24% -7.21% -- --
Loncar Cancer Immunotherapy Index -- -- -- -- -- -- --
Thomson Reuters US Biotechnology & Medical Research -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

CNCR Summary Data

Loncar
10/13/15
Open-Ended Fund
0.79%
$35.19M
$112.90K
0.38%

CNCR Portfolio Data

$22.83B
-18.97
4.96
1.93%
N/A
27

CNCR Index Data

Equal
Market Cap
Thomson Reuters US Biotechnology & Medical Research

CNCR Portfolio Management

0.79%
--
--
--

CNCR Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

CNCR Fund Structure

Open-Ended Fund
No
No
No Policy
N/A
N/A
High
Daily
Cboe Book Viewer
Top Of Book
Last 10 Trades
Bats BZX Real-time Quote -

CNCR Factset Analytics Block Liquidity

As of 09/20/19
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of CNCR. CNCR is rated a 2 out of 5.

CNCR Tradability

5,596
$112.90K
4,514
$89.48K
0.38%
$0.08
-0.14%
1.21% / -0.85%
None
100.00%
50,000
0.09
0.01%
0.74%
0
$20.12
2

CNCR Sector/Industry Breakdown


CNCR
Segment Benchmark
52.31%
55.96%
28.09%
41.69%
14.69%
--
4.91%
2.35%

CNCR Top 10 Holdings[View All]

5.11%
4.44%
4.31%
46.68%

CNCR Countries


CNCR
Segment Benchmark
79.28%
100.00%
4.54%
--
4.34%
--
4.17%
--
4.12%
--
3.55%
--

CNCR Regions


CNCR
Segment Benchmark
79.28%
100.00%
16.60%
--
4.12%
--

CNCR Economic Development


CNCR
Segment Benchmark
100.00%
100.00%

CNCR Performance Statistics

0.82
1.04
0.98
1.05
0.82%
Thomson Reuters US Biotechnology & Medical Research

CNCR MSCI ESG Ratings

BB
3.31 / 10
17.03
11.48
--
3.63%
25.70

CNCR Benchmark Comparison Holdings

27
140
13
14.11%

CNCR Benchmark Comparison Summary


CNCR
Segment Benchmark
27
140
$22.83B
$27.97B
-18.97
-135.14
4.96
4.98
0.49%
0.70%
High
High

CNCR Benchmark Comparison Market Cap Size


CNCR
Segment Benchmark
19.17%
49.65%
41.24%
32.22%
39.59%
15.58%
0.00%
2.56%